YelenaYJanjigianMD

Gastrointestinal Cancer

Chief, GI Oncology Service Memorial Sloan Kettering Cancer Center

Overview of Dr. Janjigian

Dr. Yelena Janjigian is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from New York University Grossman School of Medicine and has been in practice 14 years. Dr. Janjigian accepts several types of health insurance, listed below. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(901) 509-9141

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
New York University School of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2006 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2006 Oct 23
Completed
Phase 2
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Sep 01
Completed
Phase 2
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Nintedanib in Patients With Advanced Esophagogastric Cancer Start of enrollment: 2014 Sep 04
Completed
Phase 2
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Start of enrollment: 2016 Mar 18
Terminated
Phase 2
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Start of enrollment: 2016 Nov 03
Completed
Phase 2
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Start of enrollment: 2019 Feb 20
Active, not recruiting
Early Phase 1
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Start of enrollment: 2021 Feb 11
Active, not recruiting
Phase 2
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection Start of enrollment: 2020 Aug 10
Terminated
Phase 2
Roles: Contact, Principal Investigator
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Start of enrollment: 2024 Feb 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer Start of enrollment: 2024 Feb 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Differences in Ancestry and Presence of Gastric Precursor Lesions in Individuals With Young- and Average-Onset Gastric Cancer.
Patrick T Magahis, Nicole Cornet, Laura Tang, Kanika Arora, Neha Hingorani
Cancer Medicine. 2024-12-01
Esophagectomy may have a role in stage IV esophageal adenocarcinoma.
Marisa Sewell, Nicolas Toumbacaris, Kay See Tan, Nadia Bahadur, John Philip
The Journal of Thoracic and Cardiovascular Surgery. 2024-11-22
EGFR-directed antibodies promote HER2 ADC internalization and efficacy.
Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z Drago
Cell Reports. Medicine. 2024-11-19

Journal Articles

Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies
Sam S Yoon, Yelena Janjigian, Daniel G Coit, Zsofia K Stadler, Vivian E Strong, JAMA Surgery
YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics
Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

Biomarkers to Guide Surveillance and Adjuvant Therapy of Early-Stage Disease
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
Checkpoint Blockade in Esophagogastric Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Biomarkers for Better Treatment and Patient Selection
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Authored Content

Combination Therapies: The Wave of the FutureJanuary 2019
Checkpoint Blockade in Esophagogastric CancerJune 2018

Press Mentions

ASCO 2024: What the ESOPEC, RENAISSANCE, and ARMANI Trials Mean for the Future of Esophageal Cancer TreatmentOctober 29th, 2024
Agenus (AGEN) Q1 2023 Earnings Call TranscriptMay 9th, 2023
Transcenta to Present Two Clinical Trial Progress at ASCO 2023May 8th, 2023
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment